6,678 trials
Polycystic Ovary Syndrome (PCOS) · Overweight · Obesity
Primary: Assessment of Reproductive Functions — 5.52; 5.33 mIU/ml
Kidney Transplant Rejection · Immunosuppression
Primary: Incidence of Acute Rejection — 0 Participants
Diabetes Mellitus, Type 2
Primary: GFR (Glomerular Filtration Rate) Change After Treatment — 22; 1; 8; 0 ml/min/1.73m^2
Metabolic Syndrome
Primary: L5 Concentration in Metabolic Syndrome Patients — 35.97; 17.8233; 29.736; 23.1 mg/dL
Cataract
Primary: Best Corrected Visual Acuity (BCVA) (Pre-op) — .28 LogMar
Appendicitis · Perforated Appendicitis · Ruptured Appendicitis
Primary: Overall Cost of Care
Leukemia · Precursor b-Cell Lymphoblastic Leukemia-Lymphoma · ACUTE LYMPHOBLASTIC LEUKEMIA
Primary: Percentage of Participants With Veno-occlusive Disease (VOD) — 9.1; 14.3; 12.5; 5.3 Percentage of Participants
Breast Neoplasms · Neoplasm Metastasis
Primary: Percentage of Participants Experiencing at Least One Treatment-Emergent Adverse Event — 78.1; 69.8 percentage of participants
Sickle Cell Disease · Sickle Cell Anemia
Primary: Change From Baseline in Total Daily Physical Activity (Counts Per Minute) to Week 10-12 — -155.6 Counts per minute
Stiffness Following Total Knee Arthroplasty
Primary: Knee Range of Motion After Manipulation Under Anesthesia — 98.7; 101.2 Degrees — p=0.23
Cognitive Impairment · RRSO
Primary: Brown Attention Deficit Disorder Scale (BADDS) Change Score (End of Trial Minus Baseline). — -19.68; -4.31 score on a scale
Coronary Artery Disease · Mild Cognitive Impairment · Obesity, Abdominal
Primary: Change in Eigengene Scores — .035; -0.032 Eigen Score
Gingivitis
Primary: Mean Bleeding Index (BI) at Week 12 — 0.45; 0.76 Score on a scale — p=<0.0001
Subclinical Hypothyroidism
Primary: Participants' Willingness to Enter the Trial — 52 Participants
Intracapsular Fracture of Femur · Femoral Neck Fractures · Hip Hemiarthroplasty
Primary: Post-operative Pain — 3.29; 2.64 score on a scale